Unknown PHASE3 INTERVENTIONAL NCT00041626
Effectiveness and Safety of INGN 201 in Combination With Chemotherapy Versus Chemotherapy Alone
Sponsor: Introgen Therapeutics
Conditions
Carcinoma, Squamous Cell
Interventions
INGN 201
Updated 5 times since 2017 Last updated: Sep 10, 2007
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
A PHASE3 clinical study on Carcinoma, Squamous Cell, this trial is ongoing. The trial is conducted by Introgen Therapeutics and has accumulated 5 data snapshots since 2026. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE3
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Unknown Status PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Introgen Therapeutics
Data source: Introgen Therapeutics
For direct contact, visit the study record on ClinicalTrials.gov .